Chembio Clears Path For HIV Tests With Patent, Marketing Agreement
This article was originally published in The Gray Sheet
Executive Summary
Chembio settled its legal disputes and found a marketing partner for its recently approved rapid HIV tests in a three-party agreement announced Oct. 5
You may also be interested in...
Chembio Plans Dual Path Platform Tests For Syphilis, HIV
Chembio Diagnostics will submit a 510(k) to FDA in 2010 for its Dual Path Platform Syphilis Screen & Confirm test, according to the company
Chembio Plans Dual Path Platform Tests For Syphilis, HIV
Chembio Diagnostics will submit a 510(k) to FDA in 2010 for its Dual Path Platform Syphilis Screen & Confirm test, according to the company
Clearview rapid HIV test
Clearview Complete HIV 1/2 is the latest rapid HIV test to gain a waiver for use in physicians' offices and clinics under the Clinical Laboratory Improvements Amendments, announced Nov. 2. The test, which uses "barrel" technology developed by StatSure Diagnostic Systems to detect antibodies in blood, serum and plasma, is manufactured by Chembio and marketed and distributed worldwide by Inverness Medical Innovations. Other CLIA-waived rapid HIV tests include OraSure's OraQuick Advance, Trinity's Uni-Gold Recombigen and Chembio's HIV 1/2 Stat-Pak (1"The Gray Sheet" Oct. 9, 2006, p. 16).